CAREFULLY FORMULATED WITH POLYMERIC MESH TECHNOLOGY1
Polymeric mesh allows even distribution of active ingredients2,3
Formulated with the following inactive ingredients2,3:
- Purified water (solvent)
- Carbomer homopolymer (gelling agent)
- Propylene glycol (humectant)
- Potassium hydroxide (alkalizing agent)
![formula one](/siteassets/hcp/img/img-699x733-formula-one.png)
![formula one](/siteassets/hcp/img/img-874x449-formula-two.png)
![formula one](/siteassets/hcp/img/img-1116x390-formula-three.png)
![formula one](/siteassets/hcp/img/img-1116x390-formula-four.png)
![formula one](/siteassets/hcp/img/img-690x628-formulation-mobile.webp)
![Substraction](/siteassets/hcp/img/icon-220x283-subtraction-formula.png)
CABTREO is dispensed from a measured-dosing pump that utilizes patented polymeric mesh technology to suspend active ingredients in place for even distribution across the skin1-3
ONE SCRIPT. ONE PUMP.
ONE APPLICATION A DAY.1
With one application a day, CABTREO can become a part of your patient’s daily routine.1
![Actor portrayal of an acne patient who could be treated with CABTREO. Not an actual patient.](/siteassets/hcp/img/img-1135x1077-model-thumb.webp)
![Actor portrayal of an acne patient who could be treated with CABTREO. Not an actual patient.](/siteassets/hcp/img/img-755x1050-model-thumb-mobile.webp)
Not an actual patient.
See More
Important Safety Information AND INDICATION
CONTRAINDICATIONS
CABTREO is contraindicated in patients with:
- known hypersensitivity to clindamycin, adapalene, benzoyl peroxide, any components of the formulation, or lincomycin.
- history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
References: 1. CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% [prescribing information]. Bridgewater, NJ. Bausch Health US, LLC. 2. Ortho Dermatologics. Data on file. 3. Stein Gold L, Baldwin H, Kircik LH, et al. Efficacy and safety of a fixed‑dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate‑to‑severe acne: a randomized phase II study of the first triple‑combination drug. Am J Clin Dermatol. 2022;23(1):93-104.